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Abstract
Background: Animal studies suggest that brain apolipoprotein E (apoE) levels influence amyloid-
β (Aβ) deposition and thus risk for Alzheimer's disease (AD). We have previously demonstrated
that deletion of the ATP-binding cassette A1 transporter (ABCA1) in mice causes dramatic
reductions in brain and cerebrospinal fluid (CSF) apoE levels and lipidation. To examine whether
polymorphisms in ABCA1 affect CSF apoE levels in humans, we measured apoE in CSF taken from
168 subjects who were 43 to 91 years old and were either cognitively normal or who had mild AD.
We then genotyped the subjects for ten previously identified ABCA1  single nucleotide
polymorphisms (SNPs).
Results: In all subjects, the mean CSF apoE level was 9.09 µg/ml with a standard deviation of 2.70
µg/ml. Levels of apoE in CSF samples taken from the same individual two weeks apart were strongly
correlated (r2 = 0.93, p < 0.01). In contrast, CSF apoE levels in different individuals varied widely
(coefficient of variation = 46%). CSF apoE levels did not vary according to AD status, APOE
genotype, gender or race. Average apoE levels increased with age by ~0.5 µg/ml per 10 years (r2 =
0.05, p = 0.003). We found no significant associations between CSF apoE levels and the ten ABCA1
SNPs we genotyped. Moreover, in a separate sample of 1225 AD cases and 1431 controls, we
found no association between the ABCA1 SNP rs2230806 and AD as has been previously reported.
Conclusion: We found that CSF apoE levels vary widely between individuals, but are stable within
individuals over a two-week interval. AD status, APOE genotype, gender and race do not affect CSF
apoE levels, but average CSF apoE levels increase with age. Given the lack of association between
CSF apoE levels and genotypes for the ABCA1 SNPs we examined, either these SNPs do not affect
ABCA1 function or if they do, they do not have strong effects in the CNS. Finally, we find no
evidence for an association between the ABCA1 SNP rs2230806 and AD in a large sample set.
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Background
Alzheimer's disease (AD) is an age-related progressive
neurodegenerative disorder that causes impairments in
memory and thinking. The strongest genetic risk factor for
AD is apolipoprotein E (APOE) genotype [1]. In compari-
son to people who are homozygous for the common ε3
allele, people who carry the ε4 allele are at higher risk for
AD and generally have an earlier age of onset, while peo-
ple who carry the ε2 allele are at lower risk and have a later
age of onset [2-6]. ApoE is a chaperone for amyloid-β (Aβ)
peptide, which deposits in the brain and is thought to ini-
tiate a cascade of events that causes AD [7,8]. Mouse mod-
els have shown that the time of onset and amount of Aβ
deposition depends not only on APOE genotype but also
on apoE levels. Interestingly, higher expression of mouse
apoE increases the amount of Aβ deposition [9,10], while
higher expression of the human ε3 isoform of APOE
knocked into the mouse Apoe locus decreases levels of
amyloid deposition [11]. Additionally, expression of
human apoE in mice delays the onset of Aβ deposition in
an isoform-specific fashion, with ε2 expression decreasing
Aβ deposition the most and ε4 expression decreasing Aβ
deposition the least [12,13].
Despite evidence from animal studies suggesting that
apoE levels affect Aβ deposition, there is no consensus
regarding levels of apoE expression and its effects on Aβ
deposition in human studies. The examination of whether
apoE levels affect AD risk in humans has focused on APOE
promoter polymorphisms. Over 50 studies listed on the
Alzforum website tested for an association between AD
and one or more polymorphisms within the APOE pro-
moter [14]. Meta-analyses on this website support the
notion that APOE promoter variation is associated with
risk for AD. However, it is unclear whether this association
is due to linkage disequilibrium with the coding polymor-
phisms or whether there are independent effects on risk
due to the level of APOE expression. Some studies have
examined the effect of APOE promoter polymorphisms
on APOE expression in vitro [15,16]. More recently, allele
specific gene expression has been used in post-mortem
brain samples to measure the relative expression of APOE
ε3 and ε4 isoforms [17]. However, even these studies do
not directly examine the effect of the promoter polymor-
phisms on levels of apoE protein.
Previous studies of CSF apoE levels in humans have
reached varying conclusions. Some report that CSF apoE
levels are lower in AD subjects than in control subjects
[18-20], other studies find no association between CSF
apoE levels and AD [21,22], and one study shows that CSF
apoE levels are higher in AD subjects than in control sub-
jects [23]. Multiple studies found that the APOE genotype
was not associated with differing CSF apoE levels [19-22].
In contrast, plasma apoE levels are clearly dependent on
APOE  genotype [24,25], which suggests that apoE is
metabolized differently in the CSF and plasma. Gender
and age do not appear to affect CSF apoE levels [22].
Recently, our laboratory and others reported that apoE
levels were greatly reduced in mice lacking functional
ATP-binding cassette A1 transporter (ABCA1) [26-28].
Within the CNS of ABCA1 knock-out mice, CSF apoE was
2% of normal levels and apoE in the cortex was 20% of
normal levels [26]. ABCA1 transfers cholesterol and phos-
pholipids from the cell membrane to apolipoproteins
(including apoE) to form nascent high density lipopro-
teins (HDL). In the rare case that both copies of ABCA1
are non-functional, as occurs in Tangier's disease, apoE
and other lipoproteins do not receive normal amounts of
lipid and are rapidly degraded [29]. Multiple studies have
shown that levels of plasma HDL-C and associated apoli-
poproteins are affected by single nucleotide polymor-
phisms (SNPs) in ABCA1 [30-34]. In particular, studies
have implicated the following SNPs in affecting levels of
plasma HDL-C: rs2230806 (R219K) [33], rs2066718
(V771M) [31,32], rs2066715 (V825I) [31], rs4149313
(I883M) [34], rs2230808 (R1587K) [31]. Since ABCA1
appears to have a similar role in the CNS and in the
periphery, we hypothesized that these ABCA1 SNPs would
also have an effect on CSF apoE levels since apoE is the
major apoprotein component of HDL produced in the
CNS. Additionally, studies by others have reported that
the ABCA1 SNP rs2230806 (R219K) affects risk for AD
[35-38]. This is particularly interesting because ABCA1
falls within a region of chromosome 9 that is linked to
late-onset AD [39-43]. The profound effect of ABCA1 lev-
els on CNS apoE levels in mice, in addition to reports that
an  ABCA1  SNP may affect risk for AD, suggested that
ABCA1 may be involved in the genetic control of CNS
apoE levels in humans.
Given the contrasting results and small sample sizes used
in some studies of apoE levels in human CSF, we chose to
begin our study by characterizing CSF apoE levels in a rel-
atively large sample of 168 individuals with respect to AD
status,  APOE  genotype, gender, race and age. We next
examined whether ten ABCA1 SNPs, including five SNPs
shown to affect plasma HDL-C, affected levels of apoE in
the CSF. Finally, in a large sample of 1225 AD cases and
1431 controls, we attempted to replicate the previously
reported association between the ABCA1 SNP rs2230806
and AD.
Results
ApoE levels and stability in human CSF
ApoE levels were measured in CSF samples from 168 sub-
jects who were 43 to 91 years old (Table 1). We included
all samples available without regard to AD status, APOE
genotype, gender, race or age. ApoE values were sortedMolecular Neurodegeneration 2007, 2:7 http://www.molecularneurodegeneration.com/content/2/1/7
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into 1 µg/ml bins and the number of subjects with apoE
values within each bin from 0 to 16 µg/ml was tallied (Fig.
1A). The mean apoE level was 9.09 µg/ml with a standard
deviation of 2.70 µg/ml. The number of individuals per
bin was in a normal distribution according to a Kol-
mogorov-Smirnov test (p > 0.10).
To determine the intra-individual stability of CSF apoE
levels sampled over time, lumbar puncture was performed
on five subjects at two different times that were two weeks
apart. CSF apoE levels within the same individual were
strongly correlated (r2 = 0.93, p < 0.01). In contrast, CSF
apoE levels between different individuals showed large
variation (coefficient of variation = 46%) (Fig. 1B). This
demonstrates that CSF apoE levels are relatively stable
within an individual during a short time interval, but vary
widely between individuals. Furthermore, this suggests
that CSF apoE levels may be influenced by stable individ-
ual differences, such as genetic sequence variation.
Effects of AD status, APOE genotype, gender or age on CSF 
apoE levels
There are varying reports in the literature on whether CSF
apoE levels are affected by AD status, APOE genotype, gen-
der or age. In our relatively large sample, we investigated
whether these variables, as well as race, modified CSF
apoE levels. The levels of CSF apoE were not significantly
different between subjects who were cognitively normal
who had a clinical dementia rating (CDR) score of 0 and
those who had very mild (CDR 0.5) or mild-moderate
dementia believed to be due to AD (CDR 1+) (Fig. 2A).
Since a recent study reported that apoE levels may be
affected by APOE genotype [44], we examined whether
APOE genotype affects CSF apoE levels in our sample.
Despite large numbers of patients, we found no signifi-
cant differences in CSF apoE levels in subjects with differ-
ent APOE genotypes (Fig. 2B). Next, we looked for gender
effects on CSF apoE levels and found none (Fig. 2C). We
also found no significant difference in CSF apoE levels
between subjects who identified themselves as Caucasians
and African Americans (Fig. 2D). Additionally, we studied
whether age affects CSF apoE levels (Fig. 2E). Average
apoE levels increased by a small but significant extent,
~0.5 µg per 10 years (r2 = 0.05, p = 0.003). Finally, to test
the possibility that AD status, APOE genotype, gender and
age interact to influence apoE levels in the CSF, we per-
formed a multivariate ANOVA and found no significant
interactions. We conclude that CSF apoE levels are not
greatly affected by AD status, APOE genotype, gender or
race, but do increase with age.
Effects of ABCA1 SNPs on CSF apoE levels and risk for AD
We sought to determine whether SNPs in ABCA1 affect
CSF apoE levels. The subjects for whom we had CSF apoE
data were genotyped for the following ABCA1  SNPs:
rs2230806 (R219K), rs2066718 (V771M), rs2066715
(V825I), rs4149313 (I883M), rs2230808 (R1587K),
rs1883025 (intron), rs2275544 (intron), rs2777799
(intron), rs3904999 (intron) and rs6479283 (intron).
The numbers of subjects for which we obtained conserva-
tively called (high quality) genotypes, as well as the fre-
quencies of the minor and major alleles, are listed in Table
2. We found no association between CSF apoE levels and
any of the ABCA1 SNPs, including the five coding SNPs
that were previously associated with alterations in plasma
HDL-C levels.
We also attempted to reproduce the finding, reported by
some groups but not others, that the ABCA1 rs2230806
SNP is associated with altered risk for AD [35-38,45]. We
combined information on 794 subjects from Washington
University with 1,862 additional subjects from the Uni-
versity of California-San Diego and the United Kingdom
to yield the maximum power. The subjects from Washing-
ton University had previously been analyzed and it was
found that risk for AD in this group did not depend on the
rs2230806 SNP [36]. The 1,862 additional subjects had
not previously been used to examine the rs2230806 SNP.
In this large group of 1225 case and 1431 control subjects,
there was no effect of the rs2230806 SNP on risk for AD
(Table 3). Analysis of sub-groups based on APOE geno-
type and gender also failed to show an effect of the
rs2230806 SNP on risk for AD.
Discussion
A notable finding in this study was that CSF apoE levels
vary widely between individuals, with a range in our sam-
ple from 2 µg/ml to 16 µg/ml, but are stable within indi-
Table 1: Characteristics of subjects who underwent lumbar puncture.
CDR 0, <65 CDR 0, ≥65 CDR 0.5 CDR 1+
n = 70 55 26 17
Male 2 9 %2 8 %5 4 %4 7 %
Female 7 1 %7 2 %4 6 %5 3 %
Age* 5 4  ±  67 6  ±  87 5  ±  87 6  ±  6
ε2 freq. 0.11 0.13 0.06 0.03
ε3 freq. 0.64 0.73 0.56 0.74
ε4 freq. 0.25 0.14 0.38 0.24
*Age is mean ± standard deviationMolecular Neurodegeneration 2007, 2:7 http://www.molecularneurodegeneration.com/content/2/1/7
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viduals during an interval of 2 weeks. This suggests the
presence of stable factors within individuals, which may
be genetic or environmental, that regulate CSF apoE lev-
els. Recently, it was reported that levels of Aβ vary accord-
ing the time of day and it is possible that apoE could vary
in a similar fashion [46]. However, since all of our sam-
ples were obtained at the same time of day (8:00 am), any
diurnal variation of apoE levels in this study should be
minimal.
We examined whether AD status, APOE genotype, gender,
race or age affected CSF apoE levels, but only age was sig-
nificantly correlated. It is interesting that levels of apoE are
not elevated in carriers of the ε2 allele. ApoE3 and apoE4
both bind with high affinity to LDLR resulting in receptor-
mediated endocytosis and degradation of apoE. ApoE2
does bind to LDLR, but much less effectively than apoE3
and apoE4 [47]. In mice, the decreased affinity of apoE2
for LDLR leads to elevated levels of CSF apoE in mice in
which the human APOE  ε2 gene is knocked-in to the
mouse Apoe gene locus [48]. The lack of a difference in
apoE levels according to genotype in human CSF samples
suggests that LDLR may not have as large of an effect on
human CSF apoE levels. It will be important to assess this
issue in future studies in APOE ε2 homozygous individu-
als as there may be a much smaller effect in individuals
with one copy of the APOE ε2 gene.
We hypothesized that genetic variation in certain genes
may contribute to CSF apoE levels and examined whether
SNPs in ABCA1, especially SNPs that have been reported
to affect plasma HDL-C levels, affect CSF apoE levels. We
did not find a significant association between CSF apoE
levels and any of the ten ABCA1  SNPs we examined,
including the five coding SNPs thought to be associated
with altered HDL-C levels. Perhaps this is because the
metabolism of apoE is different in the plasma and CSF.
Alternatively, these changes in ABCA1 may not affect HDL
in the CNS as much as occurs as with HDL in the plasma.
This may be due to apoAI being the main apoprotein in
plasma HDL whereas apoE is the most abundant apopro-
tein produced in the CNS in CSF HDL. The effects of the
SNPs may also be too small to significantly affect CSF
apoE levels. However, it remains possible that rare
sequence variations that strongly influence ABCA1 func-
tion could contribute to variation in CSF apoE levels.
Recent studies demonstrate that several rare polymor-
phisms in ABCA1  collectively affect overall levels of
plasma HDL-C in the population [30,31]. Since ABCA1-
mediated lipid transport is critical in the formation of
both HDL-C in plasma and apoE-containing lipoproteins
in CSF, it is possible that the same rare ABCA1 polymor-
phisms that have large effects on plasma HDL-C levels
would also affect CSF apoE levels.
Additionally, we failed to replicate the finding of other
groups that the ABCA1 rs2230806 SNP is associated with
altered risk for AD [35-38]. We suggest three possible rea-
sons for the differing results: 1) the ABCA1 rs2230806
SNP does affect risk for AD, but the effect is small so that
the association cannot be reproduced regularly in samples
of ~2500 subjects; or 2) the population we examined was
Distribution of apoE levels in human CSF Figure 1
Distribution of apoE levels in human CSF. A, ApoE levels were sorted into bins of 1 µg/ml and the number of subjects with 
apoE values within each bin was tallied. The data represents 168 subjects without division by CDR status, APOE genotype, gen-
der, race or age. B, ApoE levels were measured in CSF samples taken two weeks apart from five different patients.Molecular Neurodegeneration 2007, 2:7 http://www.molecularneurodegeneration.com/content/2/1/7
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ApoE levels in human CSF do not vary according to presence or absence of Alzheimer's disease, level of cognitive impairment,  APOE genotype, gender or race, but do increase with age Figure 2
ApoE levels in human CSF do not vary according to presence or absence of Alzheimer's disease, level of cognitive impairment, 
APOE genotype, gender or race, but do increase with age. A, Subjects were grouped by age and AD status. Subjects with a clin-
ical dementia rating (CDR) score of 0 (cognitively normal) that were less than age 65 were placed into the first group (CDR 0, 
<65; n = 59). Subjects that were 65 and older with a CDR score of 0, 0.5, or 1–2 were placed into the second (CDR 0, n = 50), 
third (CDR 0.5, n = 21) and fourth (CDR 1+, n = 14) groups, respectively. There was no difference in CSF apoE levels by one-
way ANOVA. B, Subjects were grouped by APOE genotype into four groups: E2/E3 (n = 23), E3/E3 (n = 72), E3/E4 (n = 52), and 
E4/E4 (n = 9). There was no difference in CSF apoE levels by one-way ANOVA. C, Subjects were divided into two groups, 
female (n = 109) and male (n = 57). There was no difference in CSF apoE levels by a two-tailed Student's T-test. D, Subjects 
were grouped by self-identified racial group: African American (n = 17) and Caucasian (n = 149). There was no difference in 
CSF apoE levels by a two-tailed Student's T-test. E, CSF apoE levels were graphed as a function of subject age (n = 168). The 
slope of the regression line was 0.05, with a 95% confidence interval of 0.02 to 0.08.Molecular Neurodegeneration 2007, 2:7 http://www.molecularneurodegeneration.com/content/2/1/7
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genetically different from the populations in the other
studies assessed; or 3) the ABCA1 rs2230806 SNP does
not affect risk for AD. Since the populations that we and
others examined are similar and consisted primarily of
Caucasians with Northern European heritage, we believe
that it is most likely that the ABCA1 rs2230806 SNP con-
tributes either a very small amount or not at all to overall
risk for AD.
It seems likely that many different genes modulate levels
of apoE in the CSF. Studies suggest that LDLR and LRP
influence levels of CSF apoE in mice [48,49]. Given the
animal data, it is possible that variations in LDLR or LRP
could affect CSF apoE levels in humans, but this has not
yet been examined. Further investigation of the genetic
control of apoE levels in the CNS could uncover new
information on apoE metabolism. This research would
not only be relevant to AD, but also to a number of other
neurological diseases that may be modulated by apoE
such as stroke [50,51], multiple sclerosis [52] and trau-
matic brain injury [53]. Ultimately, an understanding of
the regulation of CSF apoE levels could lead to novel
apoE-based treatments for AD and other neurological dis-
orders.
Conclusion
We found that CSF apoE levels vary widely between indi-
viduals, but are stable within individuals over a two-week
interval. Secondly, AD status, APOE genotype, gender and
race do not affect CSF apoE levels, but CSF apoE levels do
increase with age. Additionally, ABCA1 SNPs that have
been reported to affect plasma HDL-C levels do not affect
CSF apoE levels in our sample. Finally, any association
that exists between the ABCA1 SNP rs2230806 and AD is
very weak.
Methods
Subjects
Subjects in the Washington University sample were com-
munity-living participants in the Alzheimer's Disease
Research Center (ADRC) registry. All research subjects
underwent a clinical evaluation to determine their Clini-
cal Dementia Rating (CDR), as well as a 2-hour psycho-
metric test battery. A medical history was taken to exclude
participants that might have confounding medical disor-
ders. Details of the assessment have been described previ-
ously [54-56]. Additional case control DNA samples were
from the University of California-San Diego and the
United Kingdom.
Table 2: The number of subjects with high quality genotypes and the frequency of the minor and major ABCA1 SNP alleles.
n = minor allele freq. major allele freq.
rs2230806 123 0.309 0.691
rs2066718 124 0.040 0.960
rs2066715 144 0.073 0.927
rs4149313 124 0.185 0.815
rs2230808 124 0.315 0.685
rs1883025 102 0.358 0.642
rs2275544 122 0.131 0.869
rs2777799 123 0.126 0.874
rs3904999 123 0.203 0.797
rs6479283 119 0.223 0.777
Table 3: The distribution of the rs2230806 polymorphism in subjects with Alzheimer's disease and control subjects.
# # AA # AG # GG freq. A freq. G AD vs. Control
Total AD 1225 81 476 668 0.260 0.740 p = 0.76
n = 2656 Control 1431 105 548 778 0.265 0.735
E3/E3 AD 437 31 170 236 0.265 0.735 p = 0.93
n = 1316 Control 879 63 351 465 0.271 0.729
E4/E3 AD 555 32 227 296 0.262 0.738 p = 0.10
n = 832 Control 277 18 92 167 0.231 0.769
E4/E4 AD 125 8 40 77 0.224 0.776 p = 0.86
n = 150 Control 25 1 9 15 0.220 0.780
Females AD 267 26 105 136 0.294 0.706 p = 0.99
n = 505 Control 238 23 94 121 0.294 0.706
p values are caculated by Chi Square tests with 2 degrees of freedomMolecular Neurodegeneration 2007, 2:7 http://www.molecularneurodegeneration.com/content/2/1/7
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CSF was obtained via lumbar puncture (L.P.) from 168
subjects at Washington University in the General Clinical
Research Center after obtaining informed consent. The
study protocol was approved by the Human Studies Com-
mittee at Washington University. All L.P.s were performed
at 8 am after an overnight fast with a 22 gauge atraumatic
needle. 25–30 ml of CSF was obtained from each subject
and was free of blood contamination. After collection,
CSF samples were briefly centrifuged at 1,000 × g to pellet
any cell debris, frozen, and stored in polypropylene tubes
at -80°C in 0.5 ml aliquots until analysis.
ApoE ELISA
ApoE ELISAs were performed on CSF apoE as previously
described [48]. Briefly, plates were coated overnight with
WUE4, a monoclonal antibody to human apoE [57]. The
plates were washed, blocked with 1% dry milk and
washed again. ApoE standards were purified from human
β-VLDL (BioDesign, Sako, ME). Standards and samples
were diluted and loaded onto the plate, then incubated
overnight. The plate was washed and incubated with a
polyclonal goat anti-apoE antibody (Calbiochem, San
Diego CA). The plate was washed again and incubated
with anti-goat-HRP (Vector Laboratories, Burlingame,
CA). The plate was washed once more, then developed
with TMB (Sigma, St. Louis, MO).
Genotyping
The following SNPS in ABCA1  were genotyped in the
Washington University sample of 168 subjects:
rs2230806 (R219K), rs2066718 (V771M), rs2066715
(V825I), rs4149313 (I883M), rs2230808 (R1587K),
rs1883025 (intron), rs2275544 (intron), rs2777799
(intron), rs3904999 (intron) and rs6479283 (intron).
Genotyping was performed using a modified single nucle-
otide extension reaction with allele detection by mass
spectrometry (Sequenom MassArray system; Sequenom,
San Diego, CA, USA). PCR primers, termination mixes
and multiplexing capabilities were determined with
Sequenom Spectro Designer software v2.00.17. Genotyp-
ing of rs2230806 in the large group of 2,656 subjects was
performed using allele specific real-time PCR [58]. For all
SNPs, genotypes were tested and found to be in Hardy-
Weinberg equilibrium.
Statistical analyses
Frequency distributions, correlation analysis, ANOVAs, T-
tests and Kolmogorov Smirnov tests of normality were
performed using GraphPad Prism, Version 4.00 (Graph-
Pad, San Diego, CA). Multivariate ANOVAs were per-
formed using SAS Version 9.0 for Windows XP (SAS
Institute Inc., Cary, NC).
Abbreviations
Aβ, amyloid-β peptide; ABCA1, ATP-binding cassette
transporter A1; AD, Alzheimer's disease; apoE, apolipo-
protein E; CDR, clinical dementia rating; CNS, central
nervous system; CSF, cerebrospinal fluid; ELISA, enzyme-
linked immunosorbent assay; HDL, high density lipopro-
tein; LDLR, low density lipoprotein receptor; LP, lumbar
puncture; LRP, low density lipoprotein related protein;
SNP, single nucleotide polymorphism.
Competing interests
The author(s) declare that they have no competing inter-
ests.
Authors' contributions
SEW performed the primary writing and editing of the
manuscript and was involved in experimental design, gen-
otyping and data analysis. ARS processed CSF samples
and assayed them for levels of apoE. AMF was involved in
coordinating CSF collection and experimental design. SS,
AG, KM, and HJ were involved in genotyping and experi-
mental design.
JSKK and AH were involved in experimental design and
statistical analysis. LJT provided samples from the UCSD
collection. AMG and DMH were involved in experimental
design, data analysis, and manuscript writing. All authors
approved the manuscript.
Acknowledgements
The authors gratefully acknowledge the Genetics, Clinical, Psychometric, 
and Biostatistics Cores of the Washington University ADRC for subject 
APOE genotyping and clinical, cognitive and psychometric evaluation and 
data management. We also acknowledge the contributions of our LP phy-
sicians at Washington University (Dept. of Neurology): David Holtzman, 
MD; Randall Bateman, MD; David Brody, MD, PhD; B. Joy Snider, MD, PhD; 
and Beth Ann Ward, MD. Grants: This work was supported by grants from 
the National Institute on Aging (P01 AG03991, P01 AG026276, P50 
AG05681, RO1 AG16208), a pilot grant from the Genome Sequencing 
Center at Washington University, and the Washington University General 
Clinical Research Center funded by the US Public Health System (M01 
RR00036). J.S.K.K. is funded by a Ford Foundation Predoctoral Fellowship.
References
1. Raber J, Huang Y, Ashford JW: ApoE genotype accounts for the
vast majority of AD risk and AD pathology.  Neurobiol Aging
2004, 25(5):641-650.
2. Strittmatter WJ, Saunders AM, Schmechel D, Pericak-Vance M, Eng-
hild J, Salvesen GS, Roses AD: Apolipoprotein E: high-avidity
binding to beta-amyloid and increased frequency of type 4
allele in late-onset familial Alzheimer disease.  Proc Natl Acad
Sci U S A 1993, 90(5):1977-1981.
3. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell
PC, Small GW, Roses AD, Haines JL, Pericak-Vance MA: Gene dose
of apolipoprotein E type 4 allele and the risk of Alzheimer's
disease in late onset families.  Science 1993, 261(5123):921-923.
4. Mayeux R, Stern Y, Ottman R, Tatemichi TK, Tang MX, Maestre G,
Ngai C, Tycko B, Ginsberg H: The apolipoprotein epsilon 4 allele
in patients with Alzheimer's disease.  Ann Neurol 1993,
34(5):752-754.
5. Schmechel DE, Saunders AM, Strittmatter WJ, Crain BJ, Hulette CM,
Joo SH, Pericak-Vance MA, Goldgaber D, Roses AD: IncreasedMolecular Neurodegeneration 2007, 2:7 http://www.molecularneurodegeneration.com/content/2/1/7
Page 8 of 9
(page number not for citation purposes)
amyloid beta-peptide deposition in cerebral cortex as a con-
sequence of apolipoprotein E genotype in late-onset Alzhe-
imer disease.  Proc Natl Acad Sci U S A 1993, 90(20):9649-9653.
6. Greenberg SM, Rebeck GW, Vonsattel JP, Gomez-Isla T, Hyman BT:
Apolipoprotein E epsilon 4 and cerebral hemorrhage associ-
ated with amyloid angiopathy.  Ann Neurol 1995, 38(2):254-259.
7. Wisniewski T, Ghiso J, Frangione B: Biology of A beta amyloid in
Alzheimer's disease.  Neurobiol Dis 1997, 4(5):313-328.
8. Hardy J, Selkoe DJ: The amyloid hypothesis of Alzheimer's dis-
ease: progress and problems on the road to therapeutics.  Sci-
ence 2002, 297(5580):353-356.
9. Bales KR, Verina T, Cummins DJ, Du Y, Dodel RC, Saura J, Fishman
CE, DeLong CA, Piccardo P, Petegnief V, Ghetti B, Paul SM: Apoli-
poprotein E is essential for amyloid deposition in the
APP(V717F) transgenic mouse model of Alzheimer's dis-
ease.  Proc Natl Acad Sci U S A 1999, 96(26):15233-15238.
10. Holtzman DM, Fagan AM, Mackey B, Tenkova T, Sartorius L, Paul SM,
Bales K, Ashe KH, Irizarry MC, Hyman BT: Apolipoprotein E facil-
itates neuritic and cerebrovascular plaque formation in an
Alzheimer's disease model.  Ann Neurol 2000, 47(6):739-747.
11. DeMattos RB: Apolipoprotein E dose-dependent modulation
of beta-amyloid deposition in a transgenic mouse model of
Alzheimer's disease.  J Mol Neurosci 2004, 23(3):255-262.
12. Holtzman DM, Bales KR, Tenkova T, Fagan AM, Parsadanian M, Sar-
torius LJ, Mackey B, Olney J, McKeel D, Wozniak D, Paul SM: Apoli-
poprotein E isoform-dependent amyloid deposition and
neuritic degeneration in a mouse model of Alzheimer's dis-
ease.  Proc Natl Acad Sci U S A 2000, 97(6):2892-2897.
13. Fagan AM, Watson M, Parsadanian M, Bales KR, Paul SM, Holtzman
DM:  Human and murine ApoE markedly alters A beta
metabolism before and after plaque formation in a mouse
model of Alzheimer's disease.  Neurobiol Dis 2002, 9(3):305-318.
14. Alzforum [www.alzforum.org/res/com/gen/alzgene].  .
15. Artiga MJ, Bullido MJ, Frank A, Sastre I, Recuero M, Garcia MA, Len-
don CL, Han SW, Morris JC, Vazquez J, Goate A, Valdivieso F: Risk
for Alzheimer's disease correlates with transcriptional activ-
ity of the APOE gene.  Hum Mol Genet 1998, 7(12):1887-1892.
16. Artiga MJ, Bullido MJ, Sastre I, Recuero M, Garcia MA, Aldudo J,
Vazquez J, Valdivieso F: Allelic polymorphisms in the transcrip-
tional regulatory region of apolipoprotein E gene.  FEBS Lett
1998, 421(2):105-108.
17. Bray NJ, Jehu L, Moskvina V, Buxbaum JD, Dracheva S, Haroutunian
V, Williams J, Buckland PR, Owen MJ, O'Donovan MC: Allelic
expression of APOE in human brain: effects of epsilon status
and promoter haplotypes.  Hum Mol Genet 2004,
13(22):2885-2892.
18. Blennow K, Hesse C, Fredman P: Cerebrospinal fluid apolipopro-
tein E is reduced in Alzheimer's disease.  Neuroreport 1994,
5(18):2534-2536.
19. Lehtimaki T, Pirttila T, Mehta PD, Wisniewski HM, Frey H, Nikkari T:
Apolipoprotein E (apoE) polymorphism and its influence on
ApoE concentrations in the cerebrospinal fluid in Finnish
patients with Alzheimer's disease.  Hum Genet 1995,
95(1):39-42.
20. Landen M, Hesse C, Fredman P, Regland B, Wallin A, Blennow K:
Apolipoprotein E in cerebrospinal fluid from patients with
Alzheimer's disease and other forms of dementia is reduced
but without any correlation to the apoE4 isoform.  Dementia
1996, 7(5):273-278.
21. Mulder M, Ravid R, Swaab DF, de Kloet ER, Haasdijk ED, Julk J, van
der Boom JJ, Havekes LM: Reduced levels of cholesterol, phos-
pholipids, and fatty acids in cerebrospinal fluid of Alzheimer
disease patients are not related to apolipoprotein E4.  Alzhe-
imer Dis Assoc Disord 1998, 12(3):198-203.
22. Lefranc D, Vermersch P, Dallongeville J, Daems-Monpeurt C, Petit H,
Delacourte A: Relevance of the quantification of apolipopro-
tein E in the cerebrospinal fluid in Alzheimer's disease.  Neu-
rosci Lett 1996, 212(2):91-94.
23. Lindh M, Blomberg M, Jensen M, Basun H, Lannfelt L, Engvall B, Schar-
nagel H, Marz W, Wahlund LO, Cowburn RF: Cerebrospinal fluid
apolipoprotein E (apoE) levels in Alzheimer's disease
patients are increased at follow up and show a correlation
with levels of tau protein.  Neurosci Lett 1997, 229(2):85-88.
24. Schiele F, De Bacquer D, Vincent-Viry M, Beisiegel U, Ehnholm C,
Evans A, Kafatos A, Martins MC, Sans S, Sass C, Visvikis S, De Backer
G, Siest G: Apolipoprotein E serum concentration and poly-
morphism in six European countries: the ApoEurope
Project.  Atherosclerosis 2000, 152(2):475-488.
25. Wahrle SE, Holtzman DM: Differential metabolism of ApoE iso-
forms in plasma and CSF.  Exp Neurol 2003, 183(1):4-6.
26. Wahrle SE, Jiang H, Parsadanian M, Legleiter J, Han X, Fryer JD, Kow-
alewski T, Holtzman DM: ABCA1 is required for normal central
nervous system ApoE levels and for lipidation of astrocyte-
secreted apoE.  J Biol Chem 2004, 279(39):40987-40993.
27. Hirsch-Reinshagen V, Zhou S, Burgess BL, Bernier L, McIsaac SA,
Chan JY, Tansley GH, Cohn JS, Hayden MR, Wellington CL: Defi-
ciency of ABCA1 impairs apolipoprotein E metabolism in
brain.  J Biol Chem 2004, 279(39):41197-41207.
28. Koldamova R, Staufenbiel M, Lefterov I: Lack of ABCA1 consider-
ably decreases brain ApoE level and increases amyloid dep-
osition in APP23 mice.  J Biol Chem 2005, 280(52):43224-43235.
29. Oram JF: Molecular basis of cholesterol homeostasis: lessons
from Tangier disease and ABCA1.  Trends Mol Med 2002,
8(4):168-173.
30. Cohen JC, Kiss RS, Pertsemlidis A, Marcel YL, McPherson R, Hobbs
HH: Multiple rare alleles contribute to low plasma levels of
HDL cholesterol.  Science 2004, 305(5685):869-872.
31. Frikke-Schmidt R, Nordestgaard BG, Jensen GB, Tybjaerg-Hansen A:
Genetic variation in ABC transporter A1 contributes to
HDL cholesterol in the general population.  J Clin Invest 2004,
114(9):1343-1353.
32. Probst MC, Thumann H, Aslanidis C, Langmann T, Buechler C, Patsch
W, Baralle FE, Dallinga-Thie GM, Geisel J, Keller C, Menys VC,
Schmitz G: Screening for functional sequence variations and
mutations in ABCA1.  Atherosclerosis 2004, 175(2):269-279.
33. Clee SM, Zwinderman AH, Engert JC, Zwarts KY, Molhuizen HO,
Roomp K, Jukema JW, van Wijland M, van Dam M, Hudson TJ,
Brooks-Wilson A, Genest J Jr., Kastelein JJ, Hayden MR: Common
genetic variation in ABCA1 is associated with altered lipo-
protein levels and a modified risk for coronary artery dis-
ease.  Circulation 2001, 103(9):1198-1205.
34. Wang J, Burnett JR, Near S, Young K, Zinman B, Hanley AJ, Connelly
PW, Harris SB, Hegele RA: Common and rare ABCA1 variants
affecting plasma HDL cholesterol.  Arterioscler Thromb Vasc Biol
2000, 20(8):1983-1989.
35. Wollmer MA, Streffer JR, Lutjohann D, Tsolaki M, Iakovidou V, Hegi
T, Pasch T, Jung HH, Bergmann K, Nitsch RM, Hock C, Papassotirop-
oulos A: ABCA1 modulates CSF cholesterol levels and influ-
ences the age at onset of Alzheimer's disease.  Neurobiol Aging
2003, 24(3):421-426.
36. Li Y, Tacey K, Doil L, van Luchene R, Garcia V, Rowland C, Schrodi
S, Leong D, Lau K, Catanese J, Sninsky J, Nowotny P, Holmans P,
Hardy J, Powell J, Lovestone S, Thal L, Owen M, Williams J, Goate A,
Grupe A: Association of ABCA1 with late-onset Alzheimer's
disease is not observed in a case-control study.  Neurosci Lett
2004, 366(3):268-271.
37. Katzov H, Chalmers K, Palmgren J, Andreasen N, Johansson B, Cairns
NJ, Gatz M, Wilcock GK, Love S, Pedersen NL, Brookes AJ, Blennow
K, Kehoe PG, Prince JA: Genetic variants of ABCA1 modify
Alzheimer disease risk and quantitative traits related to
beta-amyloid metabolism.  Hum Mutat 2004, 23(4):358-367.
38. Sundar PD, Feingold E, Minster RL, Dekosky ST, Kamboh MI: Gen-
der-specific association of ATP-binding cassette transporter
1 (ABCA1) polymorphisms with the risk of late-onset Alzhe-
imer's disease.  Neurobiol Aging 2006.
39. Pericak-Vance MA, Grubber J, Bailey LR, Hedges D, West S, Santoro
L, Kemmerer B, Hall JL, Saunders AM, Roses AD, Small GW, Scott
WK, Conneally PM, Vance JM, Haines JL: Identification of novel
genes in late-onset Alzheimer's disease.  Exp Gerontol 2000,
35(9-10):1343-1352.
40. Myers A, Wavrant De-Vrieze F, Holmans P, Hamshere M, Crook R,
Compton D, Marshall H, Meyer D, Shears S, Booth J, Ramic D, Know-
les H, Morris JC, Williams N, Norton N, Abraham R, Kehoe P, Wil-
liams H, Rudrasingham V, Rice F, Giles P, Tunstall N, Jones L,
Lovestone S, Williams J, Owen MJ, Hardy J, Goate A: Full genome
screen for Alzheimer disease: stage II analysis.  Am J Med Genet
2002, 114(2):235-244.
41. Blacker D, Bertram L, Saunders AJ, Moscarillo TJ, Albert MS, Wiener
H, Perry RT, Collins JS, Harrell LE, Go RC, Mahoney A, Beaty T, Fallin
MD, Avramopoulos D, Chase GA, Folstein MF, McInnis MG, Bassett
SS, Doheny KJ, Pugh EW, Tanzi RE: Results of a high-resolutionPublish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Molecular Neurodegeneration 2007, 2:7 http://www.molecularneurodegeneration.com/content/2/1/7
Page 9 of 9
(page number not for citation purposes)
genome screen of 437 Alzheimer's disease families.  Hum Mol
Genet 2003, 12(1):23-32.
42. Scott WK, Hauser ER, Schmechel DE, Welsh-Bohmer KA, Small GW,
Roses AD, Saunders AM, Gilbert JR, Vance JM, Haines JL, Pericak-
Vance MA: Ordered-subsets linkage analysis detects novel
Alzheimer disease loci on chromosomes 2q34 and 15q22.  Am
J Hum Genet 2003, 73(5):1041-1051.
43. Kehoe P, Wavrant-De Vrieze F, Crook R, Wu WS, Holmans P, Fen-
ton I, Spurlock G, Norton N, Williams H, Williams N, Lovestone S,
Perez-Tur J, Hutton M, Chartier-Harlin MC, Shears S, Roehl K, Booth
J, Van Voorst W, Ramic D, Williams J, Goate A, Hardy J, Owen MJ: A
full genome scan for late onset Alzheimer's disease.  Hum Mol
Genet 1999, 8(2):237-245.
44. Fukumoto H, Ingelsson M, Garevik N, Wahlund LO, Nukina N,
Yaguchi Y, Shibata M, Hyman BT, Rebeck GW, Irizarry MC: APOE
epsilon 3/ epsilon 4 heterozygotes have an elevated propor-
tion of apolipoprotein E4 in cerebrospinal fluid relative to
plasma, independent of Alzheimer's disease diagnosis.  Exp
Neurol 2003, 183(1):249-253.
45. Burns MP, Vardanian L, Pajoohesh-Ganji A, Wang L, Cooper M, Har-
ris DC, Duff K, Rebeck GW: The effects of ABCA1 on choles-
terol efflux and Abeta levels in vitro and in vivo.  J Neurochem
2006.
46. Bateman RJ, Wen G, Morris JC, Holtzman DM: Fluctuations of CSF
amyloid-beta levels: implications for a diagnostic and thera-
peutic biomarker.  Neurology 2007, 68(9):666-669.
47. Schneider WJ, Kovanen PT, Brown MS, Goldstein JL, Utermann G,
Weber W, Havel RJ, Kotite L, Kane JP, Innerarity TL, Mahley RW:
Familial dysbetalipoproteinemia. Abnormal binding of
mutant apoprotein E to low density lipoprotein receptors of
human fibroblasts and membranes from liver and adrenal of
rats, rabbits, and cows.  J Clin Invest 1981, 68(4):1075-1085.
48. Fryer JD, Demattos RB, McCormick LM, O'Dell MA, Spinner ML,
Bales KR, Paul SM, Sullivan PM, Parsadanian M, Bu G, Holtzman DM:
The low density lipoprotein receptor regulates the level of
central nervous system human and murine apolipoprotein E
but does not modify amyloid plaque pathology in PDAPP
mice.  J Biol Chem 2005, 280(27):25754-25759.
49. Zerbinatti CV, Wahrle SE, Kim H, Cam JA, Bales K, Paul SM, Holtz-
man DM, Bu G: Apolipoprotein E and low density lipoprotein
receptor-related protein facilitate intraneuronal Abeta 42
accumulation in amyloid model mice.  J Biol Chem 2006.
50. Nicoll JA, Burnett C, Love S, Graham DI, Dewar D, Ironside JW,
Stewart J, Vinters HV: High frequency of apolipoprotein E epsi-
lon 2 allele in hemorrhage due to cerebral amyloid angiopa-
thy.  Ann Neurol 1997, 41(6):716-721.
51. Greenberg SM, Vonsattel JP, Segal AZ, Chiu RI, Clatworthy AE, Liao
A, Hyman BT, Rebeck GW: Association of apolipoprotein E
epsilon2 and vasculopathy in cerebral amyloid angiopathy.
Neurology 1998, 50(4):961-965.
52. Chapman J, Vinokurov S, Achiron A, Karussis DM, Mitosek-Szewczyk
K, Birnbaum M, Michaelson DM, Korczyn AD: APOE genotype is
a major predictor of long-term progression of disability in
MS.  Neurology 2001, 56(3):312-316.
53. Friedman G, Froom P, Sazbon L, Grinblatt I, Shochina M, Tsenter J,
Babaey S, Yehuda B, Groswasser Z: Apolipoprotein E-epsilon4
genotype predicts a poor outcome in survivors of traumatic
brain injury.  Neurology 1999, 52(2):244-248.
54. Morris JC, McKeel DW Jr., Fulling K, Torack RM, Berg L: Validation
of clinical diagnostic criteria for Alzheimer's disease.  Ann
Neurol 1988, 24(1):17-22.
55. Morris JC, Storandt M, McKeel DW Jr., Rubin EH, Price JL, Grant EA,
Berg L: Cerebral amyloid deposition and diffuse plaques in
"normal" aging: Evidence for presymptomatic and very mild
Alzheimer's disease.  Neurology 1996, 46(3):707-719.
56. Berg L, McKeel DW Jr., Miller JP, Storandt M, Rubin EH, Morris JC,
Baty J, Coats M, Norton J, Goate AM, Price JL, Gearing M, Mirra SS,
Saunders AM: Clinicopathologic studies in cognitively healthy
aging and Alzheimer's disease: relation of histologic markers
to dementia severity, age, sex, and apolipoprotein E geno-
type.  Arch Neurol 1998, 55(3):326-335.
57. Krul ES, Tikkanen MJ, Schonfeld G: Heterogeneity of apolipopro-
tein E epitope expression on human lipoproteins: impor-
tance for apolipoprotein E function.  J Lipid Res 1988,
29(10):1309-1325.
58. Germer S, Holland MJ, Higuchi R: High-throughput SNP allele-
frequency determination in pooled DNA samples by kinetic
PCR.  Genome Res 2000, 10(2):258-266.